Description of Invention:
Ephrin receptor tyrosine kinases and their ephrin ligands have been implicated in cancer pathogenesis. Ephrin receptors and ligands affect tumor growth, invasiveness, angiogenesis, and metastasis. Ephrin signaling activities in cancer are complex and are only now beginning to be uncovered.

Researchers at the National Cancer Institute-Frederick, NIH, have developed a set of five fully-human monoclonal antibodies against human Ephrin-B2 and Ephrin type-B receptor 4 ("EphB4"). The antibodies were identified by screening a naïve human antibody phage display library against Ephrin-B2 and EphB4. These human monoclonal antibodies have high affinity and specificity for Ephrin-B2 and EphB4.

Applications:

• Research reagents for in vitro/in vivo investigation of Ephrin receptor and ligand interactions
• Targeting reagents for in vivo imaging
• Research reagents for protein co-crystallization

Advantages:

• High affinity and antigen specificity
• Bind both soluble ectodomains and cell surface-expressed molecules

Inventors:
Dimiter S Dimitrov (NCI)


Patent Status:
HHS, Reference No. E-331-2008/0
HHS, Reference No. E-331-2008/1

Research Material -- patent protection is not being pursued for this technology

Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The Center for Cancer Research Nanobiology Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information. Click here to view the NCI collaborative opportunity announcement.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Research Materials



For Additional Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220


Ref No: 2105

Updated: 06/2010